193 related articles for article (PubMed ID: 19864027)
1. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
[TBL] [Abstract][Full Text] [Related]
2. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
3. A novel human scFv fragment against TNF-alpha from de novo design method.
Chang H; Qin W; Li Y; Zhang J; Lin Z; Lv M; Sun Y; Feng J; Shen B
Mol Immunol; 2007 Jul; 44(15):3789-96. PubMed ID: 17485112
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice.
Shi J; Liu Y; Zheng Y; Guo Y; Zhang J; Cheung PT; Xu R; Zheng D
Cancer Res; 2006 Dec; 66(24):11946-53. PubMed ID: 17178893
[TBL] [Abstract][Full Text] [Related]
5. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
7. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation.
Lee BS; Kang SU; Hwang HS; Kim YS; Sung ES; Shin YS; Lim YC; Kim CH
Cancer Lett; 2012 Sep; 322(1):45-57. PubMed ID: 22353688
[TBL] [Abstract][Full Text] [Related]
8. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
9. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
10. Dimerisation strategies for shark IgNAR single domain antibody fragments.
Simmons DP; Abregu FA; Krishnan UV; Proll DF; Streltsov VA; Doughty L; Hattarki MK; Nuttall SD
J Immunol Methods; 2006 Aug; 315(1-2):171-84. PubMed ID: 16962608
[TBL] [Abstract][Full Text] [Related]
11. The primary structure and specificity determining residues displayed by recombinant salmon antibody domains.
Solem ST; Brandsdal BO; Smalås A; Jørgensen TØ
Mol Immunol; 2004 Apr; 40(18):1347-60. PubMed ID: 15072853
[TBL] [Abstract][Full Text] [Related]
12. A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells.
McClements M; Williams S; Ball C; Bristow A; Wadhwa M; Meager A
J Immunol Methods; 2008 Aug; 337(1):63-70. PubMed ID: 18625509
[TBL] [Abstract][Full Text] [Related]
13. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
15. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
[TBL] [Abstract][Full Text] [Related]
16. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
Eigenbrot C; Randal M; Presta L; Carter P; Kossiakoff AA
J Mol Biol; 1993 Feb; 229(4):969-95. PubMed ID: 8095303
[TBL] [Abstract][Full Text] [Related]
17. Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues.
Tiwari A; Khanna N; Acharya SK; Sinha S
Vaccine; 2009 Apr; 27(17):2356-66. PubMed ID: 19428851
[TBL] [Abstract][Full Text] [Related]
18. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.
Rheinnecker M; Hardt C; Ilag LL; Kufer P; Gruber R; Hoess A; Lupas A; Rottenberger C; Plückthun A; Pack P
J Immunol; 1996 Oct; 157(7):2989-97. PubMed ID: 8816407
[TBL] [Abstract][Full Text] [Related]
19. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
20. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
